Erasca Secures U.S. Patent Titled Heterocyclic Substituted Pyrimidopyran Compound And Use Thereof
Benzinga Newsdesk 8 months ago
News
The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043Expands Erasca's diversified IP portfolio for RAS-driven cancersInitial Phase 1 monotherapy data
The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043
Expands Erasca's diversified IP portfolio for RAS-driven cancers
Initial Phase 1 monotherapy data expected for ERAS-0015 in 1H and for ERAS-4001 in 2H 2026
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Patent and Trademark Office has issued Patent No. 12,552,813, titled "Heterocyclic Substituted Pyrimidopyran Compound And Use Thereof." The patent claims protect the composition of matter for Erasca's potentially first-in-class pan-KRAS inhibitor ERAS-4001 and related compositions until June 2043, which may be subject to patent term adjustments or extensions affording even later protection.